Moxifloxacin-induced tinnitus in an older adult
- PMID: 29623187
- PMCID: PMC5881981
- DOI: 10.1177/2042098618754483
Moxifloxacin-induced tinnitus in an older adult
Abstract
An increased risk of bacterial resistance toward fluoroquinolones and the increased risk of disabling and serious adverse effects prompted the US Food and Drug Administration to recommend limiting fluoroquinolone use to the treatment of community-acquired pneumonia, skin and skin-structure infections, bacterial sinusitis, plague, chronic bronchitis exacerbations, and complicated intra-abdominal infections. We report a case of moxifloxacin-induced tinnitus in an older adult prescribed oral moxifloxacin 400 mg for 5 days for the treatment of acute diverticulitis, due to allergies to nonfluoroquinolone preferred agents. A thorough literature review provided few other reported incidents of this rare and serious adverse event.
Keywords: adverse drug reaction; fluoroquinolone; moxifloxacin; tinnitus.
Conflict of interest statement
Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.
References
-
- Merck & Co., Inc. Avelox (moxifloxacin) package insert. Whitehouse Station, NJ: Merck and Co., Inc, 2016.
-
- Food and Drug Administration. FDA updates warning for fluoroquinolone antibiotics, https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm (2016, accessed 24 August 2017).
-
- Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010; 11: 79–109. - PubMed
-
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources